Welcome to ProbeChem!Global Supplier of Chemical Probes, Inhibitors & Agonists.
Chemical Structure : NCGC1481
Catalog No.: PC-72044Not For Human Use, Lab Use Only.
NCGC1481 (NCGC 1481) is a novel potent, type I kinase inhibitor against IRAK1/4 and FLT3, with IC50 of 22.6/0.8 nM and <0.5 nM respectively.
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
NCGC1481 (NCGC 1481) is a novel potent, type I kinase inhibitor against IRAK1/4 and FLT3, with IC50 of 22.6/0.8 nM and <0.5 nM respectively.
NCGC1481 exhibited potent binding affinity for IRAK1 (Kd=2.9 nM), IRAK4 (Kd=0.3 nM), and FLT3 (Kd=0.3 nM), NCGC1481 demonstrated modest selectivity (>10-fold selectivity versus more than 80% of tested kinases relative to IRAK1, IRAK4, and FLT3) against 369 kinases, inhibited 12/259 kinases with IC50 of <250 nM in the KiNativ in situ kinase profiling platform.
NCGC1481 inhibits compensatory IRAK1/4 signaling and prevents adaptive resistance in FLT3-ITD AML cells in vitro and in vivo, NCGC1481 effectively targets resistant FLT3-ITD AML xenografts.
NCGC1481 targets clinically relevant FLT3-mutant AML cells in vitro.
NCGC1481 is a potent and efficacious small-molecule inhibitor of FLT3-ITD and clinically relevant mutants (D835Y Kd=0.29 nM).
NCGC1481 exhibited superior antileukemic activity against the common, clinically relevant FLT3-mutant AML cells in vitro and in vivo.
| M.Wt | 389.463 | |
| Formula | C21H23N7O | |
| Appearance | Solid | |
| Storage |
|
|
| Solubility |
10 mM in DMSO |
|
1. Jones LM, et al. J Clin Invest. 2020 Apr 1;130(4):2017-2023.
2. Sci Transl Med. 2019 Sep 4;11(508):eaaw8828.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright
